Your browser doesn't support javascript.
loading
Brain reserve contributes to distinguishing preclinical Alzheimer's stages 1 and 2.
Yildirim, Zerrin; Delen, Firuze; Berron, David; Baumeister, Hannah; Ziegler, Gabriel; Schütze, Hartmut; Glanz, Wenzel; Dobisch, Laura; Peters, Oliver; Freiesleben, Silka Dawn; Schneider, Luisa-Sophie; Priller, Josef; Spruth, Eike Jakob; Schneider, Anja; Fliessbach, Klaus; Wiltfang, Jens; Schott, Björn-Hendrik; Meiberth, Dix; Buerger, Katharina; Janowitz, Daniel; Perneczky, Robert; Rauchmann, Boris-Stephan; Teipel, Stefan; Kilimann, Ingo; Laske, Christoph; Munk, Matthias H; Spottke, Annika; Roy, Nina; Heneka, Michael; Brosseron, Frederic; Wagner, Michael; Roeske, Sandra; Ramirez, Alfredo; Ewers, Michael; Dechent, Peter; Hetzer, Stefan; Scheffler, Klaus; Kleineidam, Luca; Wolfsgruber, Steffen; Yakupov, Renat; Schmid, Matthias; Berger, Moritz; Gurvit, Hakan; Jessen, Frank; Duzel, Emrah.
Afiliación
  • Yildirim Z; Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad., Capa Kampusu Sehremini, Fatih, 34093, Istanbul, Turkey. yildirimzerrin@gmail.com.
  • Delen F; Department of Neurology, Bagcilar Training and Research Hospital, University of Health Sciences, 34200, Istanbul, Turkey. yildirimzerrin@gmail.com.
  • Berron D; Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Vakif Gureba Cad., Capa Kampusu Sehremini, Fatih, 34093, Istanbul, Turkey.
  • Baumeister H; Department of Neurology, Basaksehir Cam and Sakura City Hospital, 34480, Istanbul, Turkey.
  • Ziegler G; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Schütze H; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Glanz W; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Dobisch L; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Peters O; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Freiesleben SD; Institute of Cognitive Neurology and Dementia Research, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Schneider LS; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Priller J; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Spruth EJ; German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
  • Schneider A; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Fliessbach K; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Wiltfang J; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Schott BH; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany.
  • Meiberth D; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Buerger K; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany.
  • Janowitz D; Department of Psychiatry and Psychotherapy, School of Medicine, Technical University of Munich, Munich, Germany.
  • Perneczky R; University of Edinburgh and UK DRI, Edinburgh, UK.
  • Rauchmann BS; German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
  • Teipel S; Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117, Berlin, Germany.
  • Kilimann I; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
  • Laske C; Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Munk MH; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
  • Spottke A; Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, University of Bonn Medical Center, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Roy N; Department of Medical Sciences, Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.
  • Heneka M; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
  • Brosseron F; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075, Goettingen, Germany.
  • Wagner M; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany.
  • Roeske S; Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075, Goettingen, Germany.
  • Ramirez A; Leibniz Institute for Neurobiology, Magdeburg, Germany.
  • Ewers M; German Center for Neurodegenerative Diseases (DZNE), Venusberg-Campus 1, 53127, Bonn, Germany.
  • Dechent P; Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62, 50924, Cologne, Germany.
  • Hetzer S; German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
  • Scheffler K; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
  • Kleineidam L; Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
  • Wolfsgruber S; German Center for Neurodegenerative Diseases (DZNE, Munich), Feodor-Lynen-Strasse 17, 81377, Munich, Germany.
  • Yakupov R; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Schmid M; Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany.
  • Berger M; Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK.
  • Gurvit H; Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany.
  • Jessen F; Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.
  • Duzel E; Department of Neuroradiology, University Hospital LMU, Munich, Germany.
Alzheimers Res Ther ; 15(1): 43, 2023 02 28.
Article en En | MEDLINE | ID: mdl-36855049
ABSTRACT

BACKGROUND:

In preclinical Alzheimer's disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain reserve in memory-related brain regions.

METHODS:

We tested whether the volumes of hippocampal subfields and parahippocampal regions were larger in individuals at stage 1 compared to asymptomatic amyloid-negative older adults (healthy controls, HCs). We also tested whether individuals with stage 2 would show the opposite pattern, namely smaller brain volumes than in amyloid-negative individuals with SCD. Participants with cerebrospinal fluid (CSF) biomarker data and bilateral volumetric MRI data from the observational, multi-centric DZNE-Longitudinal Cognitive Impairment and Dementia Study (DELCODE) study were included. The sample comprised 95 amyloid-negative and 26 amyloid-positive asymptomatic participants as well as 104 amyloid-negative and 47 amyloid-positive individuals with SCD. Volumes were based on high-resolution T2-weighted images and automatic segmentation with manual correction according to a recently established high-resolution segmentation protocol.

RESULTS:

In asymptomatic individuals, brain volumes of hippocampal subfields and of the parahippocampal cortex were numerically larger in stage 1 compared to HCs, whereas the opposite was the case in individuals with SCD. MANOVAs with volumes as dependent data and age, sex, years of education, and DELCODE site as covariates showed a significant interaction between diagnosis (asymptomatic versus SCD) and amyloid status (Aß42/40 negative versus positive) for hippocampal subfields. Post hoc paired comparisons taking into account the same covariates showed that dentate gyrus and CA1 volumes in SCD were significantly smaller in amyloid-positive than negative individuals. In contrast, CA1 volumes were significantly (p = 0.014) larger in stage 1 compared with HCs.

CONCLUSIONS:

These data indicate that HCs and stages 1 and 2 do not correspond to linear brain volume reduction. Instead, stage 1 is associated with larger than expected volumes of hippocampal subfields in the face of amyloid pathology. This indicates a brain reserve mechanism in stage 1 that enables individuals with amyloid pathologic change to be cognitively normal and asymptomatic without subjective cognitive decline.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reserva Cognitiva / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Reserva Cognitiva / Enfermedad de Alzheimer / Disfunción Cognitiva Tipo de estudio: Clinical_trials / Guideline Idioma: En Revista: Alzheimers Res Ther Año: 2023 Tipo del documento: Article